p53 single nucleotide polymorphisms and bladder cancer

被引:0
|
作者
Biros, E [1 ]
Kalina, I
Salagovic, J
Habalová, V
Hrivnák, M
Valansky, L
机构
[1] Safarik Univ, Sch Med, Dept Med Biol, Kosice 04066, Slovakia
[2] Teaching Hosp, Dept Urol, Kosice, Slovakia
关键词
bladder cancer; cancer susceptibility; p53; germ line polymorphism;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Two p53 germline polymorphisms, a BstUI in exon 4 and a MspI in intron 6 were studied using polymerase chain reaction (PCR) based methods in 50 patients with bladder cancer and 145 healthy controls. Increased frequencies of the BstUI and MspI A2 alleles were found to be associated with statistically non-significant (p = 0.2308 and p = 0.5959) but increased odd ratios for bladder cancel (OR 1.44, 95% CI 0.82-2.27 and OR 1.20, 95% CI 0.61-2.33). Statistically significant difference between patients with bladder cancer and controls was found in the distribution of MspI genotypes. There was a significantly lower proportion of the heterozygous A1A2 genotype in all patients but not in controls (p = 0.0354). The results of this study suggest that BstUI and MspI germline polymorphisms of the tumor suppressor gene p53 marginally modify the risk of bladder cancer.
引用
收藏
页码:303 / 306
页数:4
相关论文
共 50 条
  • [31] SUPERFICIAL BLADDER CANCER AND OVEREXPRESSION OF P53
    Lepara, Z.
    Junuzovic, D.
    Bajramovic, S.
    Lepara, O.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 596 - 596
  • [32] p53 and retinoblastoma pathways in bladder cancer
    Mitra, Anirban P.
    Birkhahn, Marc
    Cote, Richard J.
    WORLD JOURNAL OF UROLOGY, 2007, 25 (06) : 563 - 571
  • [33] p53 mutations in urinary bladder cancer
    P Berggren
    G Steineck
    J Adolfsson
    J Hansson
    O Jansson
    P Larsson
    B Sandstedt
    H Wijkström
    K Hemminki
    British Journal of Cancer, 2001, 84 : 1505 - 1511
  • [34] Immunotherapy of bladder cancer targeting p53
    Peralta, EA
    Liu, XP
    McCarty, TM
    Wilson, TG
    Diamond, DJ
    Ellenhorn, JDI
    JOURNAL OF UROLOGY, 1999, 162 (05): : 1806 - 1811
  • [35] p53 and treatment of bladder cancer - Reply
    Lowe, SW
    Jacks, T
    NATURE, 1997, 385 (6612) : 124 - 125
  • [36] p53 and retinoblastoma pathways in bladder cancer
    Anirban P. Mitra
    Marc Birkhahn
    Richard J. Cote
    World Journal of Urology, 2007, 25 : 563 - 571
  • [37] p53 mutations in urinary bladder cancer
    Berggren, P
    Steineck, G
    Adolfsson, J
    Hansson, J
    Jansson, O
    Larsson, P
    Sandstedt, B
    Wijkström, H
    Hemminki, K
    BRITISH JOURNAL OF CANCER, 2001, 84 (11) : 1505 - 1511
  • [38] Association between single nucleotide polymorphisms in the p53 pathway and response to radiotherapy in patients with nasopharyngeal carcinoma
    Xie, Xiaoxue
    Jin, Hekun
    Hu, Jun
    Zeng, Yong
    Zhou, Jumei
    Ouyang, Shuyu
    Yang, Wenjuan
    Hu, Bingqiang
    Wang, Hui
    ONCOLOGY REPORTS, 2014, 31 (01) : 223 - 231
  • [39] Serum p53 and bladder cancer: can serum p53 be used as a tumor marker?
    Vibhav Malviya
    Harbans Singh
    U. S. Dwivedi
      Usha
    P. B. Singh
    Urological Research, 2004, 32 : 391 - 394
  • [40] P53 POLYMORPHISMS AND HAPLOTYPES IN LUNG-CANCER
    BIRGANDER, R
    SJALANDER, A
    RANNUG, A
    ALEXANDRIE, AK
    SUNDBERG, MI
    SEIDEGARD, J
    TORNLING, G
    BECKMAN, G
    BECKMAN, L
    CARCINOGENESIS, 1995, 16 (09) : 2233 - 2236